GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

Medically reviewed by Mary Choy, PharmD Mounjaro (tirzepatide) and Trulicity (dulaglutide) are prescription medications that ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among k ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with type 2 diabetes is linked to a reduced risk of developing certain hematologic cancers compared to insulin and metformin.

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...